Roth Capital analyst Kyle Bauser resumed coverage of iRadimed (IRMD) with a Buy rating and $90 price target The firm expects the company to benefit from the launch of its next-gen non-magnetic IV infusion pump. The pump has “significant enhancements” and a premium selling price versus the older version, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: